To investigate the potential role of SPP1 expression as a biomarker for Toll-like receptor (TLR) signaling pathway inhibition in triple-negative breast cancer (TNBC), a detailed analysis was conducted using Q-omics, a comprehensive platform integrating multi-omics data and drug-screening results (http://qomics.sookmyung.ac.kr/, data obtained on 10 November 2024). This evidence concerns the gene SPP1 and triple-negative breast carcinoma.